A mutation in stratifin is responsible for the repeated epilation (Er) phenotype in mice. 2005

Bruce J Herron, and Rebecca A Liddell, and April Parker, and Sarah Grant, and Jennifer Kinne, and Jill K Fisher, and Linda D Siracusa
Genomics Institute, Wadsworth Center, NYS Dept. of Health, 465 Jordan Road, Albany, New York 12180, USA. bherron@wadsworth.org

Stratifin (Sfn, also called 14-3-3sigma) is highly expressed in differentiating epidermis and mediates cell cycle arrest. Sfn is repressed in cancer, but its function during development is uncharacterized. We identified an insertion mutation in the gene Sfn in repeated epilation (Er) mutant mice by positional cloning. Er/+ mice expressed a truncated Sfn protein, which probably contributes to the defects in Er/Er and Er/+ epidermis and to cancer development in Er/+ mice.

UI MeSH Term Description Entries
D008297 Male Males
D008817 Mice, Mutant Strains Mice bearing mutant genes which are phenotypically expressed in the animals. Mouse, Mutant Strain,Mutant Mouse Strain,Mutant Strain of Mouse,Mutant Strains of Mice,Mice Mutant Strain,Mice Mutant Strains,Mouse Mutant Strain,Mouse Mutant Strains,Mouse Strain, Mutant,Mouse Strains, Mutant,Mutant Mouse Strains,Mutant Strain Mouse,Mutant Strains Mice,Strain Mouse, Mutant,Strain, Mutant Mouse,Strains Mice, Mutant,Strains, Mutant Mouse
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D005092 Exonucleases Enzymes that catalyze the release of mononucleotides by the hydrolysis of the terminal bond of deoxyribonucleotide or ribonucleotide chains. Exonuclease,3'-5'-Exonuclease,3'-5'-Exonucleases,5'-3'-Exonuclease,5'-3'-Exonucleases,3' 5' Exonuclease,3' 5' Exonucleases,5' 3' Exonuclease,5' 3' Exonucleases
D005095 Exoribonucleases A family of enzymes that catalyze the exonucleolytic cleavage of RNA. It includes EC 3.1.13.-, EC 3.1.14.-, EC 3.1.15.-, and EC 3.1.16.-. EC 3.1.- Exoribonuclease
D006204 Hair Removal Methods used to remove unwanted facial and body hair. Depilation,Electrolytic Depilation,Epilation,Depilation, Electrolytic,Depilations,Depilations, Electrolytic,Electrolytic Depilations,Epilations,Hair Removals,Removal, Hair,Removals, Hair
D006579 Heterozygote An individual having different alleles at one or more loci regarding a specific character. Carriers, Genetic,Genetic Carriers,Carrier, Genetic,Genetic Carrier,Heterozygotes

Related Publications

Bruce J Herron, and Rebecca A Liddell, and April Parker, and Sarah Grant, and Jennifer Kinne, and Jill K Fisher, and Linda D Siracusa
November 2000, Trends in genetics : TIG,
Bruce J Herron, and Rebecca A Liddell, and April Parker, and Sarah Grant, and Jennifer Kinne, and Jill K Fisher, and Linda D Siracusa
November 1990, International journal of cancer,
Bruce J Herron, and Rebecca A Liddell, and April Parker, and Sarah Grant, and Jennifer Kinne, and Jill K Fisher, and Linda D Siracusa
January 1992, Journal of craniofacial genetics and developmental biology,
Bruce J Herron, and Rebecca A Liddell, and April Parker, and Sarah Grant, and Jennifer Kinne, and Jill K Fisher, and Linda D Siracusa
January 1982, Progress in clinical and biological research,
Bruce J Herron, and Rebecca A Liddell, and April Parker, and Sarah Grant, and Jennifer Kinne, and Jill K Fisher, and Linda D Siracusa
January 1992, Journal of craniofacial genetics and developmental biology,
Bruce J Herron, and Rebecca A Liddell, and April Parker, and Sarah Grant, and Jennifer Kinne, and Jill K Fisher, and Linda D Siracusa
December 1989, Development (Cambridge, England),
Bruce J Herron, and Rebecca A Liddell, and April Parker, and Sarah Grant, and Jennifer Kinne, and Jill K Fisher, and Linda D Siracusa
October 1987, The Journal of cell biology,
Bruce J Herron, and Rebecca A Liddell, and April Parker, and Sarah Grant, and Jennifer Kinne, and Jill K Fisher, and Linda D Siracusa
January 1979, The Journal of heredity,
Bruce J Herron, and Rebecca A Liddell, and April Parker, and Sarah Grant, and Jennifer Kinne, and Jill K Fisher, and Linda D Siracusa
January 1986, Anatomy and embryology,
Bruce J Herron, and Rebecca A Liddell, and April Parker, and Sarah Grant, and Jennifer Kinne, and Jill K Fisher, and Linda D Siracusa
September 2001, European journal of human genetics : EJHG,
Copied contents to your clipboard!